Abstract
We have analysed the mucins synthesized by the HT-29 MTX cell subpopulation, derived from the HT-29 human colon carcinoma cells through a selective pressure with methotrexate (Lesuffleuret al., 1990,Cancer Res 50: 6334–43), in the presence of benzyl-N-acetyl-α-galactosaminide (GalNAcα-O-benzyl), which is a potential competitive inhibitor of the β1,3-galactosyltransferase that synthesizes the T-antigen. The main observation was a 13-fold decrease in the sialic acid content of mucins after 24 h of exposure to 5mm GalNAcα-O-benzyl. This effect was accompanied by an increased reactivity of these mucins to peanut lectin, testifying to the higher amount of T-antigen. The second observation was a decrease in the secretion of the mucins by GalNAcα-O-benzyl treated cells. The decrease in mucin sialyation was achieved through thein situ β-galactosylation of GalNAcα-O-benzyl into Galβ1–3GalNAcα-O-benzyl, which acts as a competitive substrate of Galβ1–3GalNAc α2,3-sialyltransferase, as shown by the intracellular accumulation of NeuAcα2–3Galβ1–3GalNAcα-O-benzyl in treated cells.
Similar content being viewed by others
Abbreviations
- BSM:
-
bovine submaxillary mucin
- MTX:
-
methotrexate
- PBS:
-
sodium phosphate 10mm, NaCl 0.15m, pH 7.4 buffer
- pNp:
-
p-nitrophenol
- TBS:
-
Tris/HCl 10mm, NaCl 0.15m, pH 7.4 buffer
References
Bhavanandan VP (1991)Glycobiology 1: 493–503.
Rose MC (1992)Am Physiol Soc 263: L413–17.
Kurosaka A, Nakajima H, Funakoshi I, Matsuyama M, Nagayo T, Yamashina I (1983)J Biol Chem 258: 11594–98.
Kim YS (1992)J Cell Biochem Suppl 16G: 91–96.
Varki A (1993)Glycobiology 3: 97–130.
Pinto M, Appay MD, Simon-Assmann P, Chevalier G, Drocopoli N, Fogh J, Zweibaum A (1982)Biol Cell 44: 193–96.
Augeron C, Laboisse CL (1984)Cancer Res 44: 3961–69.
Lesuffleur T, Barbat A, Dussaulx E, Zweibaum A (1990)Cancer Res 50: 6334–43.
Maoret JJ, Font J, Augeron C, Codogno P, Baury C, Aubery M, Laboisse CL (1989)Biochem J 258: 793–99.
Lesuffleur T, Kornowski A, Luccioni C, Muleris M, Barbat A, Beaumatin J, Dussaulx E, Dutrillaux B, Zweibaum A (1991)Int J Cancer 49: 721–30.
Lesuffleur T, Porchet N, Aubert JP, Swallow D, Gum JR, Kim YS, Real FX, Zweibaum A (1993)J Cell Sci 106: 771–83.
Kuan SF, Byrd JC, Basbaum C, Kim YS (1989)J Biol Chem 264: 19271–77.
Huang J, Byrd JC, Yoon WH, Kim YS (1992)Oncol Res 4: 507–15.
DiIulio NA, Bhavanandan VP (1995)Glycobiology 5: 195–99.
Duk M, Steuden I, Dus D, Radzikowski C, Lisowska E (1992)Glycoconjugate J 9: 148–53.
Steuden I, Duk M, Czerwinski M, Radzikowski C, Lisowska E (1985)Glycoconjugate J 2: 303–14.
Huet G, Kim I, De Bolos C, Lo-Guidice JM, Moreau O, Hemon B, Richet C, Delannoy P, Real FX, Degand P (1995)J Cell Sci 108: 1275–85.
Houdret N, Perini JM, Galabert C, Scharfman A, Humbert P, Lamblin G, Roussel P (1986)Biochim Biophys Acta 880: 54–61.
De Jong JGN, Wevers RA, Sambeek RLV (1992)Clin Chem 38: 803–7.
Lamblin G, Boersma A, Klein A, Roussel P, Van Halbeek H, Vliegenthart JFG (1984)J Biol Chem 259: 9051–58.
Lo-Guidice JM, Wieruszeski JM, Lemoine J, Verbert A, Roussel P, Lamblin G (1994)J Biol Chem 269: 18794–813.
Laemmli UK (1970)Nature 227: 680–81.
Vaessen RTMJ, Kreike J, Groot GSP (1981)FEBS Lett 124: 193–96.
Peterson GL (1977)Anal Biochem 83: 346–56.
Dall'Olio F, Malagolini N, Serafini-Cessi F (1992)Biochem Biophys Res Commun 184: 1405–10.
Delannoy P, Pelczar H, Vandamme V, Verbert A (1993)Glycoconjugate J 10: 91–98.
Vandamme V, Cazlaris H, Le Marer N, Laudet V, Lagrou C, Verbert A, Delannoy P (1992)Biochimie 74: 89–100.
Schachter H, Brockhausen I (1989) InMucus and Related Topics (Chantler E, Ratcliffe NA, eds) pp. 1–26, Cambridge: Society for Experimental Biology.
Dall'Olio F, Malagolini N, Guerrini S, Serafini-Cessi F (1993)Biochem Biophys Res Commun 196: 714–20.
Capon C, Laboisse CL, Wieruszeski JM, Maoret JJ, Augeron C, Fournet B (1992)J Biol Chem 267: 19248–57.
Joziasse DH, Bergh MLE, ter Hart HGJ, Koppen PL, Hooghwinkel GJM, Van den Eijnden DH (1985)J Biol Chem 260: 4941–51.
Kuhns W, Rutz V, Paulsen H, Matta KL, Baker MA, Barner M, Granovsky M, Brockhausen I (1993)Glycoconjugate J 10: 381–94.
Author information
Authors and Affiliations
Additional information
Enzymes: CMP-NeuAc: Galβ1–3/4GlcNAc α2,3-sialyltransferase, ST3(N), EC 2.4.99.6; CMP-NeuAc: Galβ1–4GlcNAc α2,6-sialyltransferase, ST6(N), EC 2.4.99.1; CMP-NeuAc: Galβ1–3GalNAc α2,3-sialyltransferase, ST3(O), EC 2.4.99.4; CMP-NeuAc: R-GalNAcα1-O-Ser α2,6-sialyltransferase, ST6(O)-I, EC 2.4.99.3; CMP-NeuAc: NeuAcα2–3Galβ1–3GalNAc α2,6-sialyltransferase, ST6(O)-II, EC 2.4.99.7; UDP-GlcNAc: Galβ1–3GalNAc-R·(GlcNAc to GalNAc) β1,6-N-acetylglucosaminyltransferase, EC 2.4.1.102; UDP-GlcNAc: GalNAcα-R β1,3-N-acetylglucosaminyltransferase, EC 2.4.1.147; UDP-Gal: GalNAc-R β1,3-galactosyltransferase, EC 2.4.1.122.
Rights and permissions
About this article
Cite this article
Delannoy, P., Kim, I., Emery, N. et al. Benzyl-N-acetyl-α-d-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation. Glycoconjugate J 13, 717–726 (1996). https://doi.org/10.1007/BF00702335
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00702335